Hypertrophic Scar - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights

• The Hypertrophic Scar market is projected to witness consistent growth throughout the forecast period (2025-2034) due to the increasing incidence of traumatic injuries, burns, and surgical procedures worldwide, fueling the demand for effective treatment options for hypertrophic scars.
• According to the publisher, the advancements in medical technologies and innovative treatment modalities, such as laser therapy, silicone-based products, and corticosteroids, are continuously improving the efficacy of scar management, boosting the overall market expansion.
• In August 2024, Innovo Therapeutics announces that Phase II clinical results demonstrate the innovative efficacy of INV-001 for the treatment of post-thyroidectomy scars.
• In May 2023, OliX announces positive results from a Phase IIa trial of OLX10010 for hypertrophic scar treatment.
• Current treatments for hypertrophic scars include silicone sheets, pressure garments, intralesional corticosteroids, laser therapy, and surgery. However, these approaches have notable limitations, including unclear or variable efficacy, the need for prolonged use of 6-12 months, discomfort and compliance challenges, a high risk of recurrence, and potential side effects such as pain or systemic toxicity.
• The emerging drug pipeline for hypertrophic Scar is diverse and includes several promising candidates, such as, OLX101A (OliX Pharmaceuticals), INV001 (Innovo Therapeutics), and others.

The “Hypertrophic Scar - Market Insight, Epidemiology and Market Forecast - 2034” report delivers an in-depth analysis of Hypertrophic Scar epidemiology, market, and clinical development in Hypertrophic Scar. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the Hypertrophic Scar market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Hypertrophic Scar market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted Hypertrophic Scar market size from 2020 to 2034 in 7MM. The report also covers current Hypertrophic Scar treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Hypertrophic scars Understanding and Treatment Algorithm

Hypertrophic Scar Overview and Diagnosis

Hypertrophic scars are similar to keloid scars (growth of extra scar tissue), however, their growth is confined within the boundaries of the original skin defect. These scars may also appear red, and are usually thick and elevated. Hypertrophic scars usually start to develop within weeks after the injury to the skin. Hypertrophic scars may improve naturally, although this process may take up to a year or more.

Hypertrophic scar diagnosis is primarily clinical, based on a history of recent skin injury, surgery, burn, or inflammation, and the presence of a raised, firm, and often reddish scar that develops within weeks of wound closure. The scar remains confined to the original wound boundaries, distinguishing it from a keloid, which extends beyond. Patients may report symptoms such as itching, tenderness, or restricted movement over the affected area, and the scar may gradually regress over time.

The Hypertrophic scars report provides an overview of Hypertrophic scars pathophysiology and diagnostic approach Hypertrophic Scar, along with a real-world scenario of a patient’s journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Hypertrophic Scar Treatment

Hypertrophic scar and keloid management is challenging, with prevention - through trauma avoidance and prophylactic topical therapy during wound healing - being the most effective strategy. First-line treatments include occlusive dressings, compression therapy (e.g., pressure earrings, ACE/spandex bandages, button compression for earlobes), and intralesional corticosteroids such as triamcinolone (every 4-6 weeks for several months). Radiation therapy is used post-surgical excision in recurrent keloids, typically with external-beam doses of 20-25 Gy over three fractions starting the day after surgery; brachytherapy is less common. Emerging options - often as adjuvants - include interferon, 5-fluorouracil, imiquimod, tacrolimus, bleomycin, retinoic acid, botulinum toxin A, and retinoids (tretinoin, isotretinoin), which inhibit collagen synthesis and improve scar appearance.

Hypertrophic Scar Epidemiology

The hypertrophic scar epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as Incident Cases of Hypertrophic Scar, Etiologic-specific Incident Cases of Hypertrophic Scar, Total Treated Cases of Hypertrophic Scar in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• Hypertrophic Scar represents a significant clinical problem, affecting approximately 100 million patients in the developed world alone. The incidence of forming hypertrophic scars is 39% to 68% after a surgical procedure and 33% to 91% after burns.
• Those with darker skin, younger age, female and burns covering more than 20% of total body surface area (TBSA), and burns on the neck and upper limbs experience the highest likelihood of developing Hypertrophic Scar. After burn injury, nearly 75% of patients develop neuropathic pain, and factors such as scar height, pigmentation, vascularity, and hyperplasia are associated with increased pain levels.
• In surgical contexts, about 60% of patients undergoing bilateral reduction mammoplasty or median sternotomy incision develop hypertrophic scar postoperatively, with younger individuals being at higher risk.

Hypertrophic Scar Drug Chapters

The drug chapter segment of the Hypertrophic Scar report encloses a detailed analysis of Hypertrophic Scar marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into Hypertrophic Scar pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Marketed Drugs

CELACYN: IntraDerm Pharmaceuticals/Sonoma Pharmaceuticals

CELACYN Gel is a prescription-only topical formulation developed by IntraDerm Pharmaceuticals, a subsidiary of Sonoma Pharmaceuticals. It combines dimethicone (a silicone-based compound) with stabilized hypochlorous acid (HOCl) using patented MICROCYN technology. Cleared by the FDA in December 2014 via the 510(k) medical device pathway, CELACYN is indicated for the management of new and old hypertrophic and keloid scars resulting from burns, surgeries, or traumatic injuries.

In November 2024, Sonoma Pharmaceuticals announced that it would directly relaunch its prescription dermatology and eye care products in the US, including CELACYN Scar Management Gel.

MICROCYN Scar-Management Hydrogel: Oculus/Quinnova/Sonoma Pharmaceuticals

The MICROCYN Scar-Management Hydrogel is a topical gel formulated with stabilized hypochlorous acid (HOCl) using patented Microcyn technology. It’s designed to support healthy wound healing and scar management - including burns, surgical wounds, debrided wounds, and minor skin injuries by offering antimicrobial, anti-inflammatory, and soothing benefits. Initially cleared by the FDA in December 2013 (via 510(k)) under brands like MICROCYN Hydrogel and Epicyn, it has been marketed through Quinnova Pharmaceuticals/Oculus as a prescription scar management device.

In December 2024, Sonoma Pharmaceuticals secured MHRA regulatory clearance in the UK for multiple Microcyn-based products, including the scar hydrogel expanding access to the UK market.

In November 2024, Sonoma received a new FDA 510(k) clearance for its updated MICROCYN hydrogel which complements Celacyn- featuring improved biocompatibility, extended 24-month shelf life, and expanded OTC use for wounds and minor burns.

Emerging Drugs

OLX101A: OliX Pharmaceuticals/Laboratoires Théa

OLX101A is a cell-penetrating asymmetric siRNA (cp-asiRNA) therapeutic developed by OliX Pharmaceuticals (in collaboration with Hugel). It targets connective tissue growth factor (CTGF) - a key driver of fibrosis in hypertrophic and keloid scars. Unlike traditional vectors, this modified siRNA enters cells directly, suppresses CTGF production, and aims to reduce scar recurrence after surgical revision.

Hypertrophic Scar Market Outlook

Hypertrophic scar treatment is increasingly optimistic, fueled by both a strong unmet clinical need and a growing pipeline of innovative therapies. Hypertrophic scars result from abnormal wound healing and excessive collagen deposition following burns, surgeries, or deep injuries. Current treatments - including silicone gels, corticosteroid injections, pressure therapy, and laser treatments - often provide limited and inconsistent results.

Emerging therapies are now reshaping the landscape. Multiple candidates are advancing through clinical and preclinical stages, employing novel approach Hypertrophic Scar to interrupt or reverse scar formation. INV-001 from Innovo Therapeutics, for instance, is a topical small molecule that inhibits HSP47, a collagen-specific chaperone, and is currently in Phase II trials. OLX101/OLX101A, developed by OliX Pharmaceuticals, uses self-delivering siRNA to silence CTGF, a key pro-fibrotic gene, and is progressing through early clinical stages. These innovations reflect a shift from symptomatic relief toward true scar prevention and tissue regeneration. The diversity of mechanisms ranging from RNA interference and biologics to peptides and stem cells underscores the competitive intensity and scientific momentum in this space. As a result, the global hypertrophic scar treatment market is expected to grow steadily.

Overall, with advanced therapies like INV-001, OLX101, and others leading the pipeline, the hypertrophic scar treatment landscape is transitioning toward targeted, long-lasting, and biologically informed interventions - marking a major turning point in the management of hypertrophic scar.

Hypertrophic Scar drug uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025-2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Hypertrophic Scar Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Hypertrophic Scar therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.

The analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as National Institute of Allergy and Infectious Diseases USA, University of Michigan US, Washington University School of Medicine US, University Medical Center Hamburg-Eppendorf US, and University Graduate School of Medicine US etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Hypertrophic Scar market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches to Hypertrophic Scar, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Hypertrophic Scar, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Hypertrophic Scar market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Hypertrophic Scar market.

Hypertrophic Scar Report Insights

• Patient Population
• Therapeutic Approach Hypertrophic Scar
• Hypertrophic Scar Pipeline Analysis
• Hypertrophic Scar Market Size and Trends
• Existing and future Market Opportunity

Hypertrophic Scar Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Hypertrophic Scar Epidemiology Segmentation
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Hypertrophic Scar Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What is the historical and forecasted Hypertrophic Scar patient pool/patient burden in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which treatment approach Hypertrophic Scar will have a significant impact on the Hypertrophic Scar drug treatment market size?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of Hypertrophic Scar?
• How many companies are developing therapies for the treatment of Hypertrophic Scar?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Hypertrophic Scar market.
• Insights on patient burden/disease Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.